Cannabis
Rescheduling, MSOs, cannabinoid pharma, banking. The industry as a mental health market.
First reporting in this vertical publishes this week.
In the pipeline
| Program | Sponsor | Phase | Status |
|---|---|---|---|
| Zygel (CBD transdermal gel) Fragile X syndrome | Harmony Biosciences | Phase 3 | Pivotal readout expected |
| Epidiolex (cannabidiol) Epilepsy; behavioral indications explored | Jazz Pharmaceuticals | Approved | Follow-on indications in study |
| Nabiximols (Sativex) Multiple sclerosis spasticity | Jazz Pharmaceuticals | Phase 3 | U.S. program ongoing |